In this study, we demonstrate that co-transplanted primary human monocytes differentiate into CD163+ myeloid cells, both in luminal A and TN breast tumour grafts, but that the immunosuppressive MDSC-marker S100A9 (refs 37, 38) was expressed only by the CD163+ cells in the TN grafts. This evidence concerns the gene CD163 and breast neoplasm.